These inhibitors pharmacologically modulate transporter function and, if they cross the BBB, could be used to treat AD, TBI, and other brain disorders associated with NMDA-mediated excitotoxicity due to increased SLC1A4-mediated D-serine efflux from inflammatory astrocytes. This evidence concerns the gene SLC1A4 and Alzheimer disease.